-
Tunel 1-Step Assay Kits(Page)
TUNEL Assay Kits | 1-Step In Situ Apoptosis Detection | Assay Genie
PD-1 Blockade in B-Cell Lymphomas: A Comprehensive Overview(Post)Understanding PD-1 Blockade in B-Cell Lymphomas Understanding PD-1 Blockade in B-Cell Lymphomas Introduction The programmed cell death prote
Volagidemab: A Breakthrough in GLP-1 Receptor Agonists for Metabolic Disorders(Post)Quick Facts About VolagidemabWhat is Volagidemab?Volagidemab is a glucagon-like peptide-1 (GLP-1) receptor antagonist designed to regulate glucose metabolism and energy homeostasis.How D
Beyond Burnout: How T Cell Exhaustion Hijacks Cancer Immunity and What We Can Do About It(Post)Imagine a highly trained soldier, elite and effective, sent to the front lines of a relentless war. Day after day, they fight without rest, their supplies dwindle, and the enemy never stops coming. Ev
Anti-PD-1: Restoring T Cell Function in Cancer Immunotherapy(Post)Cancer immunotherapy has revolutionized the treatment landscape for various malignancies. One of the most promising therapeutic strategies is the use of immune checkpoint inhibitors, part
Dual PD-1/PD-L2 Blockade: Expanding the Horizons of Cancer Immunotherapy(Post)Introduction to PD-1, PD-L1, and PD-L2 in Cancer ImmunotherapyThe PD-1/PD-L1 immune checkpoint pathway has been instrumental in cancer immunotherapy, with PD-1 (programmed death-1) inhibi
PD-1 PD-L1 Pathway Diagram(Page) Unlocking a New Immune Checkpoint: The CD47-Thrombospondin-1 Pathway in Cancer(Post)Cancer immunotherapy has revolutionized oncology, offering powerful new ways to treat various malignancies by harnessing the body's own immune system. Central to this success are immune checkpoint inh
TIGIT/DNAM-1/CD155 (PVR) Checkpoint Axis(Page) CAR-T cell signalling(Page) Pembrolizumab: Unveiling Its Mechanism and Research Applications with Biosimilars(Post)Key Facts: PembrolizumabIs Pembrolizumab Safe?Pembrolizumab is widely recognized as safe for most patients, with side effects ranging from mild to severe. Commonly reported side effects
ELISA vs Western Blot: Which Technique Should You Choose?(Post)Written by Seán Mac Fhearraigh, PhD • Updated: 19 May 2026 • ~9 min read Quick Answer ELISA and Western Blot are both antibody-based protein detection methods. ELISA is faster, higher through
The NLRP3 inflammasome & pyroptosis(Page) Apoptosis Unveiled: Your Complete Guide to Intrinsic & Extrinsic Pathways(Post)Cell Biology · Programmed Cell DeathApoptosis: Your Complete Guide to Intrinsic & Extrinsic PathwaysApoptosis is programmed cell death — the controlled, non-inflammatory removal of damaged or unwanted
QuickStep ELISA Kits(Page)QuickStep ELISA Kits | 90-Minute 1-Wash Assays | Assay Genie
IHC Antibodies(Page)IHC Antibodies | Validated Antibodies for Accurate IHC Staining | Assay Genie
T-cell receptor (TCR) signalling(Page) DNA Ligation(Page) Cytokine neutralisation network(Page) Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
NK cell activation & innate cytotoxicity(Page) Etigilimab: Unveiling the Role of Anti-TIGIT in Cancer Research(Post)Key Facts About EtigilimabWhat is Etigilimab?Etigilimab is an anti-TIGIT monoclonal antibody being studied for its potential role in cancer immunotherapy.What role does Etigilimab play i
Questions About Dilutions? A Real Example of How to Prepare Your ELISA Solutions(Post)Quick answer A researcher preparing a Human IL-18 ELISA wasn't sure whether the protocol's “300-fold” HRP-Streptavidin step meant adding 40 µL of concentra
Myeloid reprogramming in the tumour microenvironment(Page) Ladiratuzumab Vedotin: Targeting TNBC with Next-Gen ADC Therapy(Post)Quick Facts About Ladiratuzumab VedotinWhat is Ladiratuzumab Vedotin?Ladiratuzumab Vedotin is an antibody-drug conjugate (ADC) designed to target LIV-1, a protein commonly expressed in t
Durvalumab: Advancing Immunotherapy in Cancer Treatment(Post)Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer (
Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
Fast ELISA Kits(Page)Fast ELISA Kits | Results in Under 120 Minutes | Assay Genie
In Vivo depletion atlas(Page) Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity
PD-L1 in Cancer Immunotherapy: Key Insights(Post)PD-L1 in Cancer Immunotherapy: Insights from Recent ResearchRecent advancements in cancer immunotherapy have underscored the critical role of programmed death-ligand 1 (PD-L1) in mediating immune evas
Passaging Hybridoma Cells: A Detailed Guide(Post)Cell Culture · ProtocolsPassaging Hybridoma Cells: A Detailed GuideHybridomas are productive but temperamental. They grow in suspension, are sensitive to shear and to overgrowth, and — the problem tha
Cobolimab: Unveiling TIM-3’s Role in Cancer Immunotherapy(Post)Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmun
Site Directed Mutagenesis(Page)Site-Directed Mutagenesis | Protocol, Kits & Troubleshooting | Assay Genie
Co-Immunoprecipitation (co-IP) Protocol(Page) Varlilumab: Unlocking CD27’s Potential in Cancer Research(Post)What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research(Post)What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express
Icrucumab: Exploring the Role of Anti-Angiogenic Therapy in Cancer Research(Post)Quick Facts About IcrucumabWhat is Icrucumab?Icrucumab is a monoclonal antibody that targets vascular endothelial growth factor receptor-1 (VEGFR-1) to inhibit tumor angiogenesis.How Doe
Indusatumab: Advancing Anti-CD47 Cancer Research with Biosimilar Innovations(Post)Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does
Immune-Checkpoint Inhibition in Cancer Prevention(Post)Harnessing Immune-Checkpoint Inhibition for Cancer Prevention Immune-checkpoint inhibition (ICI) has emerged as a pivotal strategy in cancer therapy, particularly in the context of tu
Understanding Zonulin and Its Role in Intestinal Health(Post)Understanding Zonulin: Key Regulator of Intestinal Barrier Function Zonulin is a crucial physiological modulator of intercellular tight junctions, playing a significant role in regulating intestinal
Daratumumab: Advancing Research in Multiple Myeloma and Beyond(Post)Key Facts About DaratumumabWhat is Daratumumab?Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells.How does Daratu
Pinatuzumab: Advancing Cancer Research and Therapeutics(Post)Quick Facts About PinatuzumabWhat is Pinatuzumab?Pinatuzumab is an antibody-drug conjugate (ADC) designed to target CD22, a protein highly expressed on B-cell malignancies, including non
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
cGAS-STING cytosolic DNA sensing(Page) Mycoplasma Troubleshooting Tips & FAQ(Page) Enhancing PD-L1 Stability Through EZH2 Inhibition(Post)Enhancing PD-L1 Stability: The Role of EZH2 InhibitionIn recent years, the role of PD-L1 (Programmed Death-Ligand 1) in cancer immunotherapy has garnered significant attention, particularly regarding
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
Trained Immunity: Reprogramming Innate Immune Memory for Future Health(Post)What if our first line of immune defense, the innate immune system, could learn from past encounters to fight future battles more effectively? For decades, we believed this was the exclusive domain of
Rosopatamab: Unveiling the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By bloc
Distributors(Page) Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics(Post)Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the me
Cetuximab: A Revolutionary Drug in Cancer Therapy(Post)Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wo
Murlentamab: Revolutionizing Cancer Research with Targeted Therapy(Post)Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst
Nadecnemab: Advancing Cancer Research Through Anti-CD47 Targeting(Post)Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
Guselkumab: Advancing Psoriasis and Autoimmune Disease Research Through IL-23 Targeting(Post)Quick Facts About GuselkumabWhat is Guselkumab?Guselkumab is a biologic therapy that selectively targets the p19 subunit of interleukin-23 (IL-23), playing a critical role in inflammator
Uliledlimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking CD
Sample Dilution Range Calculation for Competitive ELISA kits(Post)Quick answer A competitive ELISA is running correctly when the blank (zero standard) gives the highest OD, the standard curve drops smoothly with rising concentration, and your samples land in the
Canakinumab: Unraveling Its Role in Inflammatory Disease and Cancer Research(Post)Quick Facts About CanakinumabWhat is Canakinumab?Canakinumab is a human monoclonal antibody that targets interleukin-1 beta (IL-1β), reducing inflammation associated with various disease
Bevacizumab: Mechanism, Clinical Applications, and Biosimilar Insights(Post)Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne
DNA Assembly Cloning(Page) Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research(Post)Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
GeniePlex Featured Publications(Page) Monalizumab: A Breakthrough in Cancer Immunotherapy Targeting NKG2A(Post)Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking
Vopratelimab: Unlocking the Potential of ICOS in Cancer Research(Post)What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade(Post)Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin
Targeting USP22 to Boost Anticancer Immunity(Post)Targeting USP22: A New Approach to Enhance Anticancer Immunity Introduction In the ever-evolving landscape of cancer research, the intricate relationship between immune e
Sirexatamab: Advancing CD47-Targeted Cancer Therapy and Research(Post)Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Doe
T-Cell Co-Stimulation & Agonist Checkpoint Pathway(Page) Ipilimumab and Nivolumab: Advancing Research on CTLA-4 in Cancer Therapy(Post)What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod